Investigational Therapy TAK-659 Targets Lymphomas Linked to Epstein-Barr Virus, Mouse Study Shows
News
TAK-659, an investigational compound being developed by Takeda Pharmaceuticals, is able to target lymphomas associated with Epstein-Barr virus (EBV) infection, preventing their growth and spread, a mouse study shows. The ... Read more